Age-related Macular Degeneration
Conditions
Brief summary
The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.
Interventions
DRUGBevacizumab
A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Sponsors
Kumamoto University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* choroidal neovascularization caused by age-related macula degeneration * no previous treatment * a follow-up at least 12 months * a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart
Exclusion criteria
* choroidal neovascularization caused by other eye diseases * ocular surgery within the past 3 mouths * history of uveitis * intraocular pressure higher than 25 mmHg, or glaucoma * history of systemic or ocular thromboembolic events.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity | The comparison between baseline and 12-month |
Countries
Japan
Outcome results
None listed